Plasma Cell-Free Human Papillomavirus Oncogene E6 and E7 DNA Predicts Outcome in Oropharyngeal Squamous Cell Carcinoma

Henrike Reder, Victor F. Taferner, Claus Wittekindt, Andreas Braeuninger, Ernst-Jan M. Speel, Stefan Gattenloehner, Gregor Wolf, Jens P. Klussmann, Nora Wuerdemann, Steffen Wagner*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

6 Citations (Web of Science)

Abstract

Persistent human papillomavirus (HPV) infection is associated with the development of oropharyngeal squamous cell carcinoma (OPSCC), and increasing incidences of OPSCC are reported. The generally favorable treatment outcome in patients with HPV-driven OPSCC has brought de-escalation of treatment into discussion. Nevertheless, 13% to 25% develop a relapse within two years after current standard treatment. New biomarkers are urgently required to monitor therapy response, tumor burden, and minimal residual disease during follow-up. This observational study examined 50 patients with OPSCC to investigate plasma cell-free (cf) HPV-DNA derived from tumor cells before therapy and during follow-up. Real-time quantitative PCR was applied to quantify the DNA concentration of HPV oncogenes E6 and E7. A total of 85.7% of pretreatment samples from patients with HPV-driven OPSCC (n = 28) were positive for at least one marker, and cfHPV-DNA concentration increased with tumor size. Virtually no signals were detected in HPV-negative OPSCC patients (n = 20; P

Original languageEnglish
Pages (from-to)1333-1343
Number of pages11
JournalJournal of Molecular Diagnostics
Volume22
Issue number11
DOIs
Publication statusPublished - Nov 2020

Keywords

  • BARR-VIRUS DNA
  • NUCLEIC-ACIDS
  • HPV-DNA
  • HEAD
  • P16(INK4A)
  • EXPRESSION
  • RECURRENT
  • SURVIVAL
  • NSCLC
  • P16

Cite this